Floatz logo

AXUMIN

Metastatic Prostate Carcinoma

VA Greater Los Angeles Healthcare SystemSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

228 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Leuporelin
Mayo Clinic
Phase 4BBB
Abiraterone
Mayo Clinic
Phase 4BB
Prednisone
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB
Sipuleucel-T
Yale University
Phase 2BB

View all 50 →

Same molecule, other indications

AXUMIN is also rated in:

prostate carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative · Phase 4
65 / 100
View asset →
prostate cancerActive
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →